Dr Jay Edelberg: Mavacamten Is Producing Exciting Long-term Results in HCM

May 15, 2021 06:00pm

Patients with hypertrophic cardiomyopathy (HCM) had symptomatic, functional, and structural biomarker changes over the course of a little more than 6 months, explained Jay Edelberg, MD, PhD, head of Heart Failure and Cardiomyopathy Development at Bristol Myers Squibb.

Diabetes in the News: PQA Speakers Focus on Prevention, Gaps in Care
Dr Schuyler Jones: ADAPTABLE Is a Study Model for the Future
Patients Taking Mavacamten Report Big Leaps in Quality of Life
Study Identifies Potential Molecular Biomarker of Progressive MS